Global Acromegaly and Gigantism Drugs Market 2018-2022 - Key Vendors are Ipsen, Novartis & Pfizer - ResearchAndMarkets.com

DUBLIN--()--The "Global Acromegaly and Gigantism Drugs Market 2018-2022" report has been added to ResearchAndMarkets.com's offering.

The global acromegaly and gigantism drugs market to grow at a CAGR of 3.03% during the period 2018-2022.

Global Acromegaly and Gigantism Drugs Market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

The latest trend gaining momentum in the market is growing popularity of drugs over surgeries. Although pharmacological therapies for acromegaly treatment have been there for more than a decade, the demand from individuals for these non-surgical options is increasing on a regular basis. The prime reason for the shift in choice can be attributed to low success rates of acromegaly surgeries.

According to the report, one of the major drivers for this market is Strong pipeline. The presence of a large number of molecules in pipeline represents significant opportunities for market growth. Around 42.86% of the total pipeline molecules for acromegaly and gigantism are in Phase III stage of development and are expected to be launched during the forecast period. Companies are working toward the development of drugs that cater to the unmet medical needs for this condition.

For instance, octreotide capsules by Chiasma and Pasireotide long-acting release (LAR) by Novartis for individuals with acromegaly who are inadequately treated with somatostatin analogs, and combination therapy of lanreotide autogel and pegvisomant by Ipsen are in Phase III stage of development for the treatment of acromegaly.

Key vendors

  • Ipsen
  • Novartis
  • Pfizer

Key Topics Covered:

Part 01: Executive Summary

Part 02: Scope Of The Report

Part 03: Research Methodology

Part 04: Introduction

Part 05: Market Landscape

Part 06: Market Sizing

Part 07: Five Forces Analysis

Part 08: Pipeline Analysis

Part 09: Market Segmentation By Drug Class

Part 10: Customer Landscape

Part 11: Regional Landscape

Part 12: Decision Framework

Part 13: Drivers And Challenges

Part 14: Market Trends

Part 15: Vendor Landscape

Part 16: Vendor Analysis

Part 17: Appendix

For more information about this report visit https://www.researchandmarkets.com/research/clm6zm/global_acromegaly?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Endocrine and Metabolic Disorders Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Endocrine and Metabolic Disorders Drugs